JPWO2023163187A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023163187A5 JPWO2023163187A5 JP2024503297A JP2024503297A JPWO2023163187A5 JP WO2023163187 A5 JPWO2023163187 A5 JP WO2023163187A5 JP 2024503297 A JP2024503297 A JP 2024503297A JP 2024503297 A JP2024503297 A JP 2024503297A JP WO2023163187 A5 JPWO2023163187 A5 JP WO2023163187A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- set forth
- homology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022029825 | 2022-02-28 | ||
| JP2022075095 | 2022-04-28 | ||
| PCT/JP2023/007143 WO2023163187A1 (ja) | 2022-02-28 | 2023-02-27 | 神経変性疾患の治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2023163187A1 JPWO2023163187A1 (https=) | 2023-08-31 |
| JPWO2023163187A5 true JPWO2023163187A5 (https=) | 2024-10-22 |
Family
ID=87766263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503297A Pending JPWO2023163187A1 (https=) | 2022-02-28 | 2023-02-27 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250171557A1 (https=) |
| EP (1) | EP4488292A1 (https=) |
| JP (1) | JPWO2023163187A1 (https=) |
| KR (1) | KR20240139072A (https=) |
| AR (1) | AR128627A1 (https=) |
| AU (1) | AU2023226313A1 (https=) |
| CA (1) | CA3244753A1 (https=) |
| CO (1) | CO2024010819A2 (https=) |
| IL (1) | IL314246A (https=) |
| MX (1) | MX2024010163A (https=) |
| TW (1) | TW202400643A (https=) |
| WO (1) | WO2023163187A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| KR20260047599A (ko) * | 2023-08-30 | 2026-04-08 | 데이진 화-마 가부시키가이샤 | 신경 변성 질환의 치료제 |
| WO2025166040A1 (en) * | 2024-01-31 | 2025-08-07 | Alector Llc | Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6334496U (https=) | 1986-08-21 | 1988-03-05 | ||
| US6812002B2 (en) * | 2000-08-30 | 2004-11-02 | Pfizer Inc. | Osteoactivin protein and nucleic acids encoding the same, compositions and methods of stimulating bone differentiation |
| DE602005022928D1 (de) | 2004-11-30 | 2010-09-23 | Abgenix Inc | Antikörper gegen gpnmb und ihre verwendungen |
| EP1954720A1 (en) | 2005-10-31 | 2008-08-13 | The Government of the United States of America, as represented by the Secretary of Health and Human Services, National Institutes of Health | Antibodies and immunotoxins that target human glycoprotein nmb |
| KR102106821B1 (ko) * | 2018-04-27 | 2020-05-06 | 재단법인대구경북과학기술원 | 이브루티닙을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
| EP3991743A4 (en) | 2019-07-29 | 2023-08-23 | Juntendo Educational Foundation | IMMUNE INDUCTOR AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AGE-RELATED DISEASES |
-
2023
- 2023-02-24 TW TW112107020A patent/TW202400643A/zh unknown
- 2023-02-27 KR KR1020247028285A patent/KR20240139072A/ko active Pending
- 2023-02-27 AU AU2023226313A patent/AU2023226313A1/en active Pending
- 2023-02-27 EP EP23760185.1A patent/EP4488292A1/en active Pending
- 2023-02-27 MX MX2024010163A patent/MX2024010163A/es unknown
- 2023-02-27 CA CA3244753A patent/CA3244753A1/en active Pending
- 2023-02-27 WO PCT/JP2023/007143 patent/WO2023163187A1/ja not_active Ceased
- 2023-02-27 JP JP2024503297A patent/JPWO2023163187A1/ja active Pending
- 2023-02-27 IL IL314246A patent/IL314246A/en unknown
- 2023-02-27 AR ARP230100469A patent/AR128627A1/es unknown
- 2023-02-27 US US18/841,947 patent/US20250171557A1/en active Pending
-
2024
- 2024-08-08 CO CONC2024/0010819A patent/CO2024010819A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2023163187A5 (https=) | ||
| US10875909B2 (en) | Humanized antibodies that recognize alpha-synuclein | |
| KR101783058B1 (ko) | 원시섬유 형태의 베타-아밀로이드 펩티드에 대해 특이적인 인간화 항체 | |
| JP2025124705A (ja) | 胃抑制ペプチド受容体（ｇｉｐｒ）に対する結合タンパク質をｇｌｐ－１アゴニストと組み合わせて使用する、代謝障害の治療方法または寛解方法 | |
| JP7078552B2 (ja) | α－シヌクレインに対する抗体およびその使用 | |
| JP2021527656A5 (https=) | ||
| KR20190134997A (ko) | 항-tau 항체 및 이의 사용 방법 | |
| CA3046857A1 (en) | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation | |
| US20250171557A1 (en) | Therapeutic agent for neurodegenerative disorder | |
| JP2023523401A5 (https=) | ||
| JP7772715B2 (ja) | 治療用ｍｕｓｋ抗体 | |
| US20230107034A1 (en) | Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease | |
| US20250099548A1 (en) | Pharmaceutical composition for preventing or treating degenerative brain diseases, containing glucagon-like peptide-1 and interleukin-1 receptor antagonist | |
| RU2024124415A (ru) | Терапевтический агент для нейродегенеративного заболевания | |
| KR102655944B1 (ko) | 항-아밀로이드 베타 항체 및 이의 사용 방법 | |
| AU2024332186A1 (en) | Therapeutic agent for neurodegenerative diseases | |
| HK40120105A (en) | Therapeutic agent for neurodegenerative disorder | |
| CN119529081A (zh) | Aβ初原纤维抗体或其功能性片段及其应用 | |
| KR20260042555A (ko) | 알츠하이머병 치료제의 개발 및 용도 | |
| CN119343367A (zh) | 卵泡抑素融合蛋白 | |
| WO2024123052A1 (ko) | 항-타우 항체 및 펩티드를 포함하는 융합체와 그의 용도 | |
| CN118459582A (zh) | 一种抗焦谷氨酸修饰的β淀粉样蛋白抗体及其用途 | |
| HK40126393A (zh) | Aβ初原纤维抗体或其功能性片段及其应用 |